How to Manage Warfarin Management
|
|
- Georgina Robertson
- 8 years ago
- Views:
Transcription
1 How to Manage Warfarin Management Katie McClendon, PharmD, BCPS University of Mississippi School of Pharmacy AS MANDATED BY ACCME SPEAKERS ARE ASKED TO DISCLOSE ANY REAL OR APPARENT CONFLICT RELATED TO THE CONTENT OF THEIR PRESENTATION TODAY S SPEAKER HAS NO DISCLOSURE TO MAKE Objectives 1. Describe the CHEST Antithrombotic Guidelines for warfarin management 2. Recognize common and serious drug drug interactions with warfarin and develop plans for managing the interaction 3. Manage non therapeutic anticoagulation *If time, will discuss new anticoagulant options 1
2 Warfarin Indications Prevention and treatment of venous thromboembolism (VTE), atrial fibrillation (AF), mechanical valve replacement Contraindications Hypersensitivity Hemorrhagic tendencies Severe uncontrolled or malignant hypertension Pericarditis or pericardial effusion Patients with a high potential of noncompliance Eclampsia/pre eclampsia Pregnancy (except women with mechanical heart valves) Vitamin K Antagonist Warfarin (Coumadin, Jantoven) Racemic mixture of R and S enantiomers. S enantiomer is 3 5 x more potent MOA: inhibits the C1 subunit of the VKORC1 enzyme complex, thus reducing regeneration of vitamin K depletion of clotting factors II, VII, IX, X and proteins C and S SN0T (Seven, nine, 10, and two) 2
3 Chest Guidelines 2008 version was 968 pages, 600 recommendations Can you remember all that? 2012 Update now has 70 page executive summary, total 801 pages guidelines 9th ed now available Included a systematic review of patient values and preferences Used more tables to make content easier to follow and understand Guyatt GH, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9 th Ed: American College of Chest Physicians evidence based clinical practice guidelines (9 th ed). Chest 2012; 141 (2): 7S 47S. TOP 10 VKA RECOMMENDATIONS IN CHEST GUIDELINES Starting Warfarin Start warfarin at 10 mg daily x 2 days in generally healthy patients to be treated outpatient Then check INR Recommend against pharmacogenetic testing to guide initial dose For VTE, start LMWH and warfarin same time 3
4 Continued Warfarin Don t bother bridging for single subtherapeutic INR in a patient who is normally therapeutic If INR <0.5 out of range in a stable patient, recheck in 1 2 weeks If stable, check INR q12 weeks (not q4 weeks) INR Goals Most need INR 2 3 (goal 2.5) Including: Antiphospholipid syndrome with hx of VTE, AF, aortic valve replacement Mechanical mitral valve replacement INR (goal 3) Chest Guidelines: DDI to Avoid Increased risk of bleeding, so avoid the following if possible: NSAIDs, COX 2 inhibitors, some antibiotics Exception: mechanical valve, ACS, recent coronary stents/bypass surgery WORST Cotrimoxazole Quinolones PROBABLE Cephalosporins Metronidazole Amoxicillin Doxycycline Fluconazole 4
5 Nursing Home Patient New patient to the nursing home, on long list of medications, including therapeutic warfarin (INR 2.51) and metronidazole Metronidazole therapy completed about 1 week after coming to nursing home What do you expect to happen to the INR? Increase Decrease No change Stopping Warfarin Just stop it VTE after surgery: 3 months VTE with transient RF: 3 months Unprovoked VTE: at least 3 months 2 or more VTE: extended treatment DVT+CA: extended treatment AF cardioversion: start >3 weeks prior, continue >4 weeks after Mechanical valves: continued therapy Don t Stop Til You Get Enough MJ diagnosed with LLE DVT while taking Yaz 3/1/13 You switch to IUD. When can you stop warfarin? 6/1/13 9/1/13 3/1/14 Never 5
6 Warfarin Therapy 9th ed. Update PRACTICE 8 TH EDITION 9 TH EDITION Loading dose Bridging for patients with acute VTE None; start at 5 10 mg for 1 2 days then adjust based on INR (1B) Start warfarin on day 1 of LMWH or UFH (1A) 10 mg for 2 days in patients sufficiently healthy to be treated outpatient (2C) Start warfarin on day 1 or 2 of LMWH or UFH (2C) Monitoring No less frequent than every 4 weeks for those on stable doses (2C) Single out of range Not previously stated INR Bridging for low INR Monitor at intervals up to 12 weeks for those on stable doses (2B) If INR <0.5 above or below target INR, continue current dose and retest in 1 2 weeks (2C) Not recommended (2C) Vitamin K supplementation Discontinuation Not previously stated Abrupt (2C) Regular supplementation not recommended (2C) Warfarin Kinetics R warfarin s ½ life=45 h S warfarin s ½ life=29h S: CYP2C9, 3A4 2C9 has multiple polymorphisms R: 3A4, 1A2, 2C19 Starting Doses Warfarin Patient Characteristics Healthy and to be treated as outpatients 10 mg Dose Elderly, impaired nutrition, liver disease, CHF, or high risk of bleeding Heart valve replacement 5mg 2 3 mg Check INR in 2 3 days and adjust accordingly to target INR INR of 2 3 for most indications INR of for some high risk indications Mechanical heart valve 6
7 Warfarin: Factors Affecting INR Increased Effect ( Increased INR) Hyperthyroidism Liver disease Fever Diarrhea/Vomiting HF exacerbation Decreased intake of Vitamin K Acute alcohol use Decreased tobacco/smoking Decreased Effect (Decreased INR) Hypothyroidism Fat malabsorption Increased intake of Vitamin K Chronic alcohol use Increased smoking Increased exercise Warfarin Drug Drug Interactions Increased effect/inr Amiodarone* Propafenone* Metronidazole* Tamoxifen* Bactrim (SMX/TMP)* Cimetidine Corticosteroids Azoles Alcohol Levothyroxine Macrolides (rarely Azithromycin) Phenytoin Omeprazole Decreased Effect/INR Phenobarbital Phenytoin Primidone Rifampin* Carbamazepine Methimazole PTU *major interaction Case example My grandmother: 92 yo with Afib, HF, OP with multiple fractures/falls Fosamax, amiodarone, warfarin, HCTZ Warfarin monitored at cardiologist office Diagnosed with UTI at PCP, given Bactrim DS Pharmacists filled Bactrim without contacting either provider 7
8 Common, Mild Interactions APAP (higher dose) Still safest option for OTC pain relief Alcohol, including rubbing alcohol Foods Cranberry, grapefruit, other tropical fruits (?) Vit K intake changes Warfarin Side Effects Bleeding! gums, nose, mouth, stools, urine Skin necrosis (rare) Purple toe syndrome Monitoring INR Check After warfarin initiation 2 3 days Until INR in therapeutic range on 2 consecutive INR checks Then every week Until INR in therapeutic range on 2 consecutive INR checks Then every 2 weeks Until INR in therapeutic range on 2 consecutive INR checks Then every 4 weeks When dose is stable, check monthly INR Check for maintenance of warfarin After 1 week If start/stop an interacting medication, diet change, etc. Every 1 2 weeks If dose needed adjustment by 5 10% Every 4 weeks Every 6 12 weeks* If patient maintained on stable dose <6 months If patient maintained on stable dose > 6 months INR Goal 2 3 UMC Warfarin Nomogram Dosage Adjustment INR Goal INR < 2.0 Increase weekly dose by 5 20% INR < 2.5 INR No change INR INR Decrease weekly dose by 0 15% INR INR Hold 0 1 doses, then decrease weekly dose by 10 15% INR INR Hold 1 2 doses, then decrease weekly dose by 10 20% INR INR Hold 2 3 doses, monitor INR more frequently, and restart at a dose 10 20% lower. The patient will be counseled to watch for signs and symptoms of bleeding and to go to the emergency department if bleeding occurs.* INR INR 9.0 INR > 11 Patient to hold medication until directed and will be seen at next clinic day. The patient will be counseled to watch for signs and symptoms of bleeding and to go to the emergency department if bleeding occurs.* If phytonadione (Vitamin K 1) is deemed necessary, oral Vitamin K 1 2.5mg may be prescribed. Patient may be sent to the emergency room.* PT/INR will be repeated and CBC drawn. Physician will be contacted. Patient may be sent to the emergency room. INR 9.0 INR > 11 8
9 Vitamin K 9 th ed. Update 8 TH EDITION 9 TH EDITION INR <5 with no bleeding: lower warfarin dose (1C) INR >5 but <9 with no bleeding: hold 1 or 2 doses and lower the warfarin dose (1C) INR > 4.5 but < 10 with no bleeding: vitamin K NOT recommended (2B) INR > 10: give low dose vitamin K orally (2C) INR >5 but <9 with risk of bleeding: hold dose and give vitamin K 1 or 2.5 mg PO (2A) INR >5 but <9 requiring surgery: vitamin K PO (will drop INR in 24 hours) (2C) INR > 9 with no bleeding: hold doses and give vitamin K 2.5 mg or 5 mg PO (1B) Serious bleeding regardless of INR: hold warfarin and give vitamin K 10 mg IV slow + FFP, PCC, or recombinant factor VIIa (1C) For major bleeding, give PCC instead of plasma (2C) Additional use of vitamin K 5 10 mg by slow IV injection recommended in addition to reversal with coagulation factors (2C) Warfarin and Pregnancy? Pregnancy Category X, so generally avoid, especially 1 st trimester VTE: LMWH If dx in pregnancy, continue tx at least 6 weeks post partum If trying to conceive, wait until pregnant to switch to LMWH Mechanical valve: LMWH or UFH (monitor anti Xa or appt) Can switch to warfarin after 13 weeks until close to delivery TOP 10 THINGS NOT TO DO WITH A WARFARIN PATIENT 9
10 Top 10 things to not do with a warfarin patient Follow up in 4 weeks after initial visit Taper warfarin off Continue current warfarin dose if after 1 day the INR is therapeutic Assume that because a patient has a therapeutic INR, there are no problems Prescribe ABX without scheduling close follow up Top 10 things to not do with a warfarin patient Leave a patient on warfarin without periodically re evaluating risk/benefit Forget to ensure use of contraception in women of child bearing potential Over react to sub/supra therapeutic INRs Use Vit K if INR <10 and no bleed Tell patients they can t eat Vit K foods QUESTIONS? 10
11 WHAT ABOUT THOSE NEW MEDS? Direct Thrombin Inhibitor Dabigatran (Pradaxa) MOA: Specific, reversible, direct thrombin inhibitor that inhibits both free and fibrin bound thrombin. Inhibits thrombin mediated effects Fibrinogen fibrin Activation of factors V, VIII, XI, and XIII Thrombin mediated platelet aggregations 11
12 Dabigatran (Pradaxa) US Indication: Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation Canadian indication: Prevention of VTE in patients undergoing total hip or knee replacement surgery Contraindications: Hypersensitivity Active pathological bleed Dabigatran vs. Warfarin Chest guidelines recommend dabigatran over warfarin if: AF+TIA/CVA Dabigatran (Pradaxa) Dosing and Conversions Patient Characteristics Dose CrCl > 30 ml/min 150 mg BID CrCl ml/min and concomitant Consider 75 mg BID dronedarone or ketoconazole CrCl ml/min 75 mg BID Conversion from parenteral Initiate dabigatran 2 hours prior to the time anticoagulant of the next scheduled parenteral anticoagulant (enoxaparin) or at the time of D/C of continuous parenteral anticoagulant (heparin) Conversion from warfarin D/C warfarin and initiate when INR < 2.0 Conversion to warfarin: Initiation of warfarin based on CrCl CrCl >50 ml/min: initiate 3 days before D/C of dabigatran CrCl ml/min: 2 days before D/C of dabigatran CrCl ml/min: 1 day before D/C of dabigatran 12
13 Common Side Effects Gastritis like symptoms Bleeding (mostly GI) Monitoring Efficacy None Required Safety Renal function at baseline and yearly in patients >75 yo and those with CrCl < 50 ml/min Antidote None Dabigatran (Pradaxa) Of note: Pregnancy Category C Storage Concerns Once bottles are opened, must use within 4 months! Keep in original package; protect from moisture. Factor Xa Inhibitor Rivaroxaban (Xarelto) MOA: Inhibits platelet activation and fibrin clot formation by direct, selective, and reversible inhibition of Factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin which then activates the conversion of fibrinogen fibrin = clot! 13
14 Rivaroxaban (Xarelto) Indications Stroke prevention in patients with nonvalvular Atrial fibrillation Post Operative DVT/PE prophylaxis Knee replacement surgery Hip replacement surgery Contraindications Hypersensitivity Active major bleeding Moderate to severe hepatic impairment associate with coagulopathy (Canadian labeling) Rivaroxaban (Xarelto) Dosing Patient Characteristic CrCl > 50 ml/min Non valvular Atrial Fibrillation Dosing 20 mg po daily with evening meal CrCl ml/min 15 mg po daily with evening meal Post Operative Thromboprophylaxis Knee Replacement 10 mg once daily x days. Initiate 6 10 hours postoperatively Hip Replacement 10 mg once daily x 35 days. Initiate 6 10 hours postoperatively Rivaroxaban (Xarelto) Conversion Conversion from warfarin Action Discontinue warfarin and initiate rivaroxaban as soon as INR <3.0 Conversion to warfarin Conversion from continuous IV heparin Initiate warfarin and a parenteral anticoagulant 24 hours after D/C rivaroxaban Initiate rivaroxaban at the time of heparin discontinuation Conversion to continuous heparin Initiate heparin 24 hours after D/C of rivaroxaban 14
15 Rivaroxaban (Xarelto) Common Side Effects Bleeding Headache Monitoring None Antidote None Black Box Warnings: Patients receiving spinal epidural or spinal puncture are at risk of hematoma and paralysis D/C of therapy in patients with AF can put patients at increased risk of thrombotic events Other 9 th ed. Updates TOPIC 8 TH EDITION 9 TH EDITION Dabigatran Not included Recommended OVER warfarin for patients with atrial fibrillation needing oral anticoagulation (2B) Rivaroxaban Not included Recommended as a prophylactic option for total hip/knee arthroplasty patients, orthopedic patients who are uncooperative with injections or an IPCD LMWH recommended over dabigatran or rivaroxaban for long term therapy in patients with DVT or PE who are not receiving VKA therapy (2B/2C). Apixaban (Eliquis) Direct factor Xa inhibitor Approved for stroke prevention in AF Dose: 5 mg BID 2.5 mg BID if 2 or more of the following: >80 yoa, weight <60 kg, SCr>1.5 mg/dl 15
16 Apixaban (Eliquis) DDI: avoid with inducers of CYP3A4 and P glycoprotein Carbamazepine, phenytoin, phenobarbital, St. John s wort, rifampin Monitoring: None Antidote: NONE Number needed to treat and harm For Atrial Fibrillation (vs. warfarin): Eliquis (apixaban) 3 fewer strokes per 1000 patients per year, 10 FEWER bleeds, and 4 FEWER deaths Pradaxa (dabigatran) 5 fewer strokes per 1000 patients per year; similar overall bleeding risk Xarelto (rivaroxaban) similar strokes and risk of major bleeding BUT only one given once/day Warfarin: only one with an antidote, only one for mechanical valves, and treatment costs less ($80 vs $250). Pharmacists Letter 16
17 QUESTIONS? 17
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationMore information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationAdvances in An+coagula+on
Advances in An+coagula+on Laurajo Ryan PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Aus+n College of Pharmacy UTHSCSA School of Medicine Pharmcotherapy Research Educa+on
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationNew Oral Anticoagulants for VTE, A-fib, and ACS
New Oral Anticoagulants for VTE, A-fib, and ACS KCUMB Fall CME 2014 September 18, 2014 Schoen W. Kruse, Ph.D. Assistant Dean Associate Professor of Pharmacology KCUMB An 82 y/o male presents to the ED
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationThings to Consider when Starting Patients on Warfarin
Things to Consider when Starting Patients on Warfarin 1. Ensure that patient doesn t have any of these absolute contraindication for warfarin 1 Pregnancy, except in women with mechanical heart valves Hemorrhagic
More informationNews Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com
News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationHow To Increase Warfarin
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology daniel.forman@readinghealth.org 610 509 5067 cell RHS Anticoagulation
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationTimeline: FDA approval of NOACs. FDA-approved oral anticoagulants. FDA-approved oral anticoagulants. Stroke risk reductions: afib RCTs 4/8/2016
Christina York, PharmD, BCPS Pharmacology Conference April 2016 Objectives Compare current FDA-approved oral anticoagulants Understand practical issues that arise with novel oral anticoagulants Consider
More informationClinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationNovel Anticoagulants
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationNew Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationSNAPSHOT OF ANTITHROMBOTIC THERAPY WITH A FOCUS
SNAPSHOT OF ANTITHROMBOTIC THERAPY WITH A FOCUS ON THE PERIOPERATIVE PERIOD A PHARMACIST S PERSPECTIVE Katie Cinnamon, PharmD, BCPS Clinical Pharmacist DISCLOSURE The content of this presentation is based
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationGuideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )
Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-950:2014-2 Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto ) 1.
More information